Skip to main content
TEVA
NYSE Life Sciences

Teva Beats Q3 Estimates, Lifts 2026 Revenue and EPS Outlook

Tom Rudovsky · Reported by Seeking Alpha
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$41.6
Mkt Cap
$47.428B
52W Low
$19.975
52W High
$42.59
52W Position info
108% above low
Off High info
2.3% below high
Rel. Volume info
1.9× avg
Market data snapshot near publication time

TEVA has more than doubled off its 52-week low of $19.975 on elevated volume (1.9× avg).

Summary

Teva beat Q3 expectations and raised full-year guidance, with revenue of $4.4B topping consensus by $170M and adjusted EPS of $0.86 beating by $0.14. The quarter's engine was the innovative portfolio: Austedo, Ajovy and Uzedy together added about $1.1B globally, up 33% year over year in local currency, with Ajovy up 61% and Uzedy up 96%. That offset a 16% local-currency decline in global generics, driven by lower U.S. lenalidomide (generic Revlimid) sales tied to Bristol Myers' multiple myeloma franchise. Management now sees 2026 revenue of $16.7B-$17B and adjusted EPS of $1.92-$2.11, up from $16.5B-$16.85B and $1.91-$2.11, and the biosimilar business is tracking above $800M for 2026, a year ahead of plan. Adjusted gross margin improved to 58.7% from 55.3%, a sign the mix shift toward brands is lifting profitability. The stock is trading near its 52-week high, so the guidance raise is the key test of whether the growth pivot holds.

At the time of this announcement, TEVA was trading at $41.60 on NYSE in the Life Sciences sector, with a market capitalization of approximately $47.4B. The 52-week trading range was $19.98 to $42.59. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Seeking Alpha.


Price Chart

Share this article

Copied!

TEVA - Latest Insights

TEVA
Nov 19, 2026, 1:17 PM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $39.18
Real-time Price: $38.20 info
Change: -$0.9851 (-3%) info
Market Cap: $44.97B info
TEVA
Nov 18, 2026, 5:07 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $42.21
Real-time Price: $38.20 info
Change: -$4.01 (-10%) info
Market Cap: $44.97B info
TEVA
Nov 16, 2026, 12:36 PM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $43.62
Real-time Price: $38.20 info
Change: -$5.42 (-12%) info
Market Cap: $44.97B info
TEVA
Nov 11, 2026, 12:33 PM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $42.86
Real-time Price: $38.20 info
Change: -$4.66 (-11%) info
Market Cap: $44.97B info
TEVA
Oct 09, 2026, 11:21 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $41.62
Real-time Price: $38.20 info
Change: -$3.42 (-8%) info
Market Cap: $44.97B info